Hairy Cell Leukemia Clinical Trial
Official title:
Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.
PRIMARY OBJECTIVES: I. To demonstrate the efficacy in achieving complete response of combination of cladribine administered intravenously over 2 hours for 5 days followed by rituximab weekly for 8 weeks in patients with untreated or previously treated hairy cell leukemia. II. To examine the efficacy of rituximab to eradicate minimal residual disease (MRD) after cladribine therapy (as assessed by immunophenotyping of bone marrow and peripheral blood). III. To examine the effect of addition of rituximab to cladribine on the long term disease-free (DFS) and overall survival (OS) (as compared with historical controls). IV. To evaluate potential predictors of outcome including molecular and flow evaluations of MRD, as well as other potential molecular predictors such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF). OUTLINE: Patients receive cladribine intravenously (IV) over 2 hours once daily (QD) on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05645744 -
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
|
||
| Active, not recruiting |
NCT03805932 -
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
|
Phase 1 | |
| Recruiting |
NCT04324112 -
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
|
Phase 2 | |
| Active, not recruiting |
NCT01711632 -
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
|
Phase 2 | |
| Withdrawn |
NCT03739606 -
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00923013 -
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
|
Phase 2 | |
| Completed |
NCT00898079 -
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
|
||
| Completed |
NCT01720758 -
Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
|
N/A | |
| Recruiting |
NCT04815356 -
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
|
Phase 1 | |
| Recruiting |
NCT02131753 -
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
|
Phase 2/Phase 3 | |
| Completed |
NCT00321555 -
LMB-2 to Treat Hairy Cell Leukemia
|
Phase 2 | |
| Completed |
NCT00586924 -
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
|
Phase 1 | |
| Recruiting |
NCT06340737 -
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05388123 -
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
|
Phase 2 | |
| Not yet recruiting |
NCT05859932 -
Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
|
||
| Recruiting |
NCT04952974 -
B-cell Chronic Lymphoid Malignancies Markers
|
||
| Recruiting |
NCT04775745 -
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
|
Phase 1 | |
| Completed |
NCT03010358 -
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01059786 -
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
|
Phase 2 | |
| Recruiting |
NCT04322383 -
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
|
Phase 2 |